Prezcobix Patent Expiration

Prezcobix is a drug owned by Janssen Products Lp. It is protected by 19 US drug patents filed from 2015 to 2018. Out of these, 4 drug patents are active and 15 have expired. Prezcobix's patents have been open to challenges since 27 August, 2016. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 06, 2032. Details of Prezcobix's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire.
US8148374 Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(4 years from now)

Active
US7700645 Pseudopolymorphic forms of a HIV protease inhibitor
Dec, 2026

(2 years from now)

Active
US8518987 Pseudopolymorphic forms of a HIV protease inhibitor
Feb, 2024

(7 months ago)

Expired
USRE43596 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
May, 2017

(7 years ago)

Expired
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718 Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(7 years from now)

Active
US7700645

(Pediatric)

Pseudopolymorphic forms of a HIV protease inhibitor
Jun, 2027

(2 years from now)

Active
US8518987

(Pediatric)

Pseudopolymorphic forms of a HIV protease inhibitor
Aug, 2024

(a month ago)

Expired
US8597876

(Pediatric)

Method of treating HIV infection
Dec, 2019

(4 years ago)

Expired
US7470506

(Pediatric)

Fitness assay and associated methods
Dec, 2019

(4 years ago)

Expired
US7470506 Fitness assay and associated methods
Jun, 2019

(5 years ago)

Expired
US8597876 Method of treating HIV infection
Jun, 2019

(5 years ago)

Expired
US9889115 Fitness assay and associated methods
Jun, 2019

(5 years ago)

Expired
USRE43596

(Pediatric)

α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
Nov, 2017

(6 years ago)

Expired
USRE42889

(Pediatric)

α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
Apr, 2017

(7 years ago)

Expired
USRE43802

(Pediatric)

α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
Apr, 2017

(7 years ago)

Expired
USRE43802 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
Oct, 2016

(7 years ago)

Expired
USRE42889 α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
Oct, 2016

(7 years ago)

Expired
US5843946

(Pediatric)

α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
Jun, 2016

(8 years ago)

Expired
US5843946 α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
Dec, 2015

(8 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Prezcobix's patents.

Given below is the list of recent legal activities going on the following patents of Prezcobix.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 20 Sep, 2023 US8148374 (Litigated)
Expire Patent 21 Mar, 2022 US9889115
Payment of Maintenance Fee, 4th Year, Large Entity 26 Jan, 2022 US10039718
Expire Patent 10 Jan, 2022 US8597876 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 06 Oct, 2021 US7700645
Maintenance Fee Reminder Mailed 04 Oct, 2021 US9889115
Maintenance Fee Reminder Mailed 26 Jul, 2021 US8597876 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 10 Feb, 2021 US8518987
Expire Patent 01 Feb, 2021 US7470506
Maintenance Fee Reminder Mailed 17 Aug, 2020 US7470506


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Prezcobix and ongoing litigations to help you estimate the early arrival of Prezcobix generic.

Prezcobix's Litigations

Prezcobix been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 09, 2015, against patent number US8518987. The petitioner Lupin Limited, challenged the validity of this patent, with Janssen Sciences Ireland UC as the respondent. Click below to track the latest information on how companies are challenging Prezcobix's patents.

Last updated on October 8, 2024
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8518987 April, 2015 Terminated-Denied
(16 Oct, 2015)
Janssen Sciences Ireland UC Lupin Limited


FDA has granted some exclusivities to Prezcobix. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Prezcobix, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Prezcobix.

Exclusivity Information

Prezcobix holds 1 exclusivities. All of its exclusivities have expired in 2017. Details of Prezcobix's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 27, 2017

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Several oppositions have been filed on Prezcobix's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Prezcobix's generic, the next section provides detailed information on ongoing and past EP oppositions related to Prezcobix patents.

Prezcobix's Oppositions Filed in EPO

Prezcobix has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Mar 06, 2015, by Alfred E. Tiefenbacher (Gmbh & Co. Kg). This opposition was filed on patent number EP10180831A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP16180589A Oct, 2020 Cooke, Richard Granted and Under Opposition
EP16180589A Oct, 2020 Teva Pharmaceutical Industries Ltd. Granted and Under Opposition
EP16180589A Jan, 2020 STADA Arzneimittel AG Granted and Under Opposition
EP14168686A Apr, 2018 Cooke, Richard Opposition rejected
EP12167591A May, 2017 Cooke, Richard Revoked
EP12167590A May, 2017 Cooke, Richard Revoked
EP12167590A May, 2017 Teva Pharmaceutical Industries LTD. Revoked
EP12167591A May, 2017 Teva Pharmaceutical Industries LTD. Revoked
EP12167589A May, 2017 Cooke, Richard Granted and Under Opposition
EP12167589A May, 2017 Teva Pharmaceutical Industries Ltd. Granted and Under Opposition
EP12167596A Apr, 2017 Cooke, Richard Revoked
EP12167596A Apr, 2017 Teva Pharmaceutical Industries Ltd Revoked
EP09739981A Jun, 2016 Cooke, Richard Revoked
EP09739981A Jun, 2016 Teva Pharmaceutical Industries Ltd Revoked
EP10703766A Apr, 2016 Cooke, Richard Revoked
EP10703766A Apr, 2016 Teva Pharmaceutical Industries Ltd Revoked
EP07836007A Mar, 2016 Trösch, Dominique Granted and Under Opposition
EP07836007A Mar, 2016 Georg Kalhammer/Stephan Teipel Granted and Under Opposition
EP07836007A Mar, 2016 Teva Pharmaceutical Industries LTD. Granted and Under Opposition
EP03753571A Mar, 2015 Wittkopp, Alexander Patent maintained as amended
EP10180831A Mar, 2015 Wittkopp, Alexander Patent maintained as amended
EP10180831A Mar, 2015 Strawman Limited Patent maintained as amended
EP03753571A Mar, 2015 Strawman Limited Patent maintained as amended
EP03753571A Mar, 2015 Alfred E. Tiefenbacher (GmbH & Co. KG) Patent maintained as amended
EP10180831A Mar, 2015 Alfred E. Tiefenbacher (GmbH & Co. KG) Patent maintained as amended


US patents provide insights into the exclusivity only within the United States, but Prezcobix is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Prezcobix's family patents as well as insights into ongoing legal events on those patents.

Prezcobix's Family Patents

Prezcobix has patent protection in a total of 39 countries. It's US patent count contributes only to 12.9% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Prezcobix.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Prezcobix's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 06, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Prezcobix Generics:

There are no approved generic versions for Prezcobix as of now.

How can I launch a generic of Prezcobix before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Prezcobix's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Prezcobix's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Prezcobix -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
800 mg/150 mg 24 Jul, 2020 1 06 Oct, 2032

Alternative Brands for Prezcobix

Prezcobix which is used for managing HIV-1 infection in adults and pediatric patients., has several other brand drugs using the same active ingredient (Cobicistat; Darunavir). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Janssen Prods
Symtuza






About Prezcobix

Prezcobix is a drug owned by Janssen Products Lp. It is used for managing HIV-1 infection in adults and pediatric patients. Prezcobix uses Cobicistat; Darunavir as an active ingredient. Prezcobix was launched by Janssen Prods in 2015.

Approval Date:

Prezcobix was approved by FDA for market use on 29 January, 2015.

NCE-1 date:

NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Prezcobix is 29 January, 2015, its NCE-1 date is estimated to be 27 August, 2016.

Active Ingredient:

Prezcobix uses Cobicistat; Darunavir as the active ingredient. Check out other Drugs and Companies using Cobicistat; Darunavir ingredient

Treatment:

Prezcobix is used for managing HIV-1 infection in adults and pediatric patients.

Dosage:

Prezcobix is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
150MG;800MG TABLET Prescription ORAL